KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Research & Development (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Research & Development data on record, last reported at $27.3 million in Q3 2025.

  • For Q3 2025, Research & Development fell 22.21% year-over-year to $27.3 million; the TTM value through Sep 2025 reached $116.4 million, down 4.7%, while the annual FY2024 figure was $120.9 million, 5.91% up from the prior year.
  • Research & Development reached $27.3 million in Q3 2025 per NKTR's latest filing, down from $29.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $107.3 million in Q1 2022 and bottomed at $24.1 million in Q3 2023.
  • Average Research & Development over 5 years is $49.5 million, with a median of $30.5 million recorded in 2025.
  • Peak YoY movement for Research & Development: tumbled 71.59% in 2023, then skyrocketed 45.54% in 2024.
  • A 5-year view of Research & Development shows it stood at $99.6 million in 2021, then tumbled by 65.13% to $34.7 million in 2022, then fell by 13.81% to $29.9 million in 2023, then dropped by 4.0% to $28.7 million in 2024, then decreased by 5.19% to $27.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $27.3 million in Q3 2025, $29.9 million in Q2 2025, and $30.5 million in Q1 2025.